Tylenol Lawsuits Revived by Appeals Court

A U.S. appeals court on Monday revived hundreds of lawsuits alleging that children developed autism or ADHD after their mothers took Tylenol during pregnancy. The appellate judges reversed a district court judge's decision to dismiss these cases, citing that the lower court overstepped by excluding scientific evidence presented by expert witnesses for the plaintiffs.

The ruling acknowledged the ongoing national debate surrounding acetaminophen, the active ingredient in Tylenol. While some studies suggest a possible slight increase in risk, major medical groups, including the American College of Obstetricians and Gynecologists, continue to recommend Tylenol as the safest pain relief option during pregnancy. Untreated fevers during pregnancy can pose significant risks to both mother and fetus.

The primary expert for the plaintiffs, Dr. Andrea Baccarelli, presented a report claiming substantial evidence supported a causal link between prenatal acetaminophen use and neurodevelopmental disorders. However, the district court judge had previously deemed his testimony unreliable, stating he had misrepresented study results. The appeals court, however, found the disputed scientific information to be valid, noting that reasonable scientists do disagree on this matter.

Kenvue, the maker of Tylenol since 2023, stated that the procedural ruling does not alter the fact that credible science shows no proven link between acetaminophen and autism or ADHD. The company intends to continue defending these cases and emphasizes its confidence in the safety of its product. The appeals court cautioned that their ruling does not establish a causal relationship but addresses the scrutiny of expert testimony.